Analysts Issue Forecasts for PVLA FY2024 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Research analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Palvella Therapeutics in a research note issued on Thursday, December 26th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($4.37) for the year. HC Wainwright has a “Buy” rating and a $38.00 price target on the stock.

Separately, Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $12.00 on Monday. The firm has a market capitalization of $15.84 million, a P/E ratio of -0.99 and a beta of 0.61. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $22.32.

Insider Buying and Selling at Palvella Therapeutics

In other news, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were purchased at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the transaction, the director now owns 180,671 shares of the company’s stock, valued at $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.39% of the company’s stock.